All the news Showing 10 of 15 articles from: Deciding when and how to treat HCVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources EASL issues new hepatitis C treatment recommendations for all genotypes Liz Highleyman / 26 September 2016 The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris. The updated guidelines now include highly ... HCV treatment is effective and may work as prevention for people who inject drugs Liz Highleyman / 19 September 2016 Hepatitis C treatment for people who inject drugs is as safe and effective as it is for non-drug-users – with cure rates exceeding 90% – and treating enough people in this population could ... US study provides 'real world' evidence about which patients with hepatitis C should be prioritised for therapy Michael Carter / 19 October 2015 For patients with hepatitis C virus (HCV) mono-infection, baseline fibrosis stage is strongly predictive of the medium-term risk of serious liver disease and death, investigators from the United States report in the ... New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment Keith Alcorn / 07 October 2015 A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta – EDP-239 – was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at ... Liver function and survival improve after treatment with Viekirax + Exviera regimen Liz Highleyman / 27 June 2015 People with hepatitis C who were treated with AbbVie's Viekirax plus Exviera or '3D' regimen saw improvements in liver function biomarkers, had better quality of life and had increased survival compared to ... Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients Keith Alcorn / 13 May 2015 Shortening hepatitis C treatment to 6 weeks for easier-to-treat patients without cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with genotype 1 infection, according to results of a ... Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough Liz Highleyman / 13 May 2015 A six-week regimen of sofosbuvir (Sovaldi) plus two experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis C virus and no liver ... Another study confirms detrimental effects of delaying hepatitis C treatment Liz Highleyman / 05 May 2015 Deferring antiviral therapy for hepatitis C until a person progresses to advanced liver disease has clear drawbacks including lower treatment effectiveness and an increased risk of clinical events and death, according to ... Deferring hepatitis C treatment can lead to liver cancer and death, despite cure Liz Highleyman / 05 March 2015 People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured – with outcomes worsening the ... One million people with hepatitis C in the US at high priority for treatment Liz Highleyman / 07 January 2015 An estimated 813,000 people with diagnosed hepatitis C in the US have undergone liver disease staging and meet the 'highest' or 'high' priority criteria for immediate treatment, according to an analysis presented ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive